Breaking Finance News

EXACT Sciences (NASDAQ:EXAS) price target upped to $23.00, released a ratings update earlier today by Jefferies & Co

Boasting a price of $19.27, EXACT Sciences (NASDAQ:EXAS) traded 2.07% higher on the day. With the last stock price close up 57.53% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. EXACT Sciences has recorded a 50-day average of $19.57 and a two hundred day average of $12.21. Volume of trade was down over the average, with 735,065 shares of EXAS changing hands under the typical 4,079,220

Stating a potential upside of 0.19%, Jefferies & Co increased the stock price target of EXACT Sciences (NASDAQ:EXAS) to $23.00

Performance Chart


With a total market value of $0, EXACT Sciences has with a one year low of $4.67 and a one year high of $22.80 .

A total of 10 equity analysts have released a ratings update on EXAS. Five equity analysts rating the company a strong buy, one equity analyst rating the company a buy, seven equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $8.55.

Brief Synopsis About EXACT Sciences (NASDAQ:EXAS)

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company's product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. It has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test. The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers. It also focused on developing its pipeline for future products and services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.